NASDAQ:ADMS - Adamas Pharmaceuticals, Inc.
$6.28
 $-0.12
-1.87%
4:00PM EDT
2019-04-18
Adamas Pharmaceuticals, Inc. is a pharmaceutical company. The Company is engaged in developing medicines to manage the daily lives of those affected by chronic neurologic disorders. It offers a platform based on an understanding of time dependent biologic effects of disease activity and drug response to achieve relief without tolerability issues. It has developed a portfolio of chrono-synchronous therapies to address chronic neurologic disorders. Its first product candidate is ADS-5102, a chrono-synchronous amantadine therapy, for the treatment of levodopa-induced dyskinesia (LID) in patients with Parkinson's disease (PD). It has completed Phase II proof-of-concept study of ADS-5102 in these patients. Its Phase III clinical program included three placebo-controlled trials: EASED, EASE LID and EASE LID 3. Its second product candidate is ADS-4101, an extended-release version of single-agent compound for the treatment of epilepsy (partial onset seizures). Read more at  reuters.com
sector:  health care
industry:  biotechnology
the data below are updated and published after 9pm EDT each trading day
  ADMS     avg for
industry  
  avg for
sector  
42 stocks weight:  0. 44   199. 07   233. 87  
42 stocks rank:  3. 93 K 1. 43 K 1. 06 K
# analyst opinions:  9. 00   14. 48   14. 09  
mean recommendation:  2. 30   2. 09   2. 01  

quick ratio:  8. 95   5. 29   1. 92  
current ratio:  9. 41   5. 64   2. 40  

target price low:  5. 00   84. 50   115. 74  
target price avg:  6. 10   110. 73   137. 39  
target price high:  9. 16   136. 41   157. 80  
1-yr high:  32. 67   114. 11   138. 85  
last close:  6. 28   87. 56   116. 78  
50-day avg:  8. 36   95. 43   123. 53  
200-day avg:  14. 58   94. 13   121. 20  
1-yr low:  6. 28   72. 67   98. 41  
volume:  607. 97 K 2. 43 M 4. 85 M
50-day avg volume:  609. 09 K 2. 72 M 4. 97 M
200-day avg volume:  590. 63 K 2. 90 M 4. 58 M

1-day return:  -1. 88 % -0. 40 % 0. 07 %
this week return:  -2. 48 % -5. 72 % -4. 11 %
12-wk return:  -28. 47 % 1. 78 % -0. 04 %
52-wk return:  -72. 79 % 10. 81 % 14. 09 %

enterprise value (EV):  85. 02 M 51. 19 B 117. 96 B
market cap:  172. 37 M 43. 00 B 104. 52 B
EBITDA:  -113. 56 M 4. 45 B 8. 01 B
enterprise multiple (EV/EBITDA):  -0. 75   4. 34   13. 27  
enterprise/revenue (EV/R):  2. 50   68. 16   13. 68  
total revenue:  34. 05 M 10. 61 B 38. 24 B
total debt:  119. 12 M 12. 22 B 16. 66 B
debt/equity:  132. 53   46. 86   89. 46  
net income (common):  -131. 00 M 2. 20 B 4. 21 B

shares outstanding:  27. 45 M 570. 91 M 1. 24 B
shares:  16. 64 M 571. 02 M 1. 23 B
shares short:  5. 75 M 9. 93 M 16. 79 M
shares short prior month:  5. 38 M 9. 96 M 16. 58 M
short ratio:  7. 35   5. 31   3. 30  
total cash/share:  7. 68   11. 13   9. 30  
total cash:  210. 87 M 6. 70 B 7. 10 B
free cash flow:  -73. 40 M 3. 58 B 4. 74 B
operating cash flow:  -104. 22 M 4. 14 B 6. 32 B

book value:  3. 28   12. 76   26. 84  
price/book:  1. 92   3. 08   -1. 74  
operating margins:  -337. 85 % -721. 97 % -88. 82 %
EBITDA margins:  0. 00 % 10. 94 % 22. 54 %
profit margins:  0. 00 % 7. 81 % 10. 60 %
gross margins:  98. 14 % 37. 02 % 55. 68 %

1-yr max volatility:  -32. 84 % --- ---
1-yr mean volatility:  -0. 46 % 0. 03 % 0. 04 %

1-yr EPS:  -4. 87   2. 39   4. 08  
forward EPS:  -2. 52   3. 97   7. 14  
P/E:  -1. 29   13. 59   22. 83  
forward P/E:  -2. 56   -20. 05   14. 49  
PE/G:  -0. 00   -1. 46   1. 68  
growth:  2244. 20 % 126. 81 % 29. 29 %
earnings high:  -1. 07   1. 02   1. 63  
earnings avg:  -1. 15   0. 76   1. 51  
earnings low:  -1. 31   0. 47   1. 39  
revenue high:  14. 22 M 2. 68 B 10. 71 B
revenue avg:  12. 16 M 2. 59 B 10. 49 B
revenue low:  9. 00 M 2. 49 B 10. 25 B
return on assets:  -34. 15 % -2. 80 % 5. 29 %
return on equity:  -167. 94 % -18. 52 % 7. 38 %
revenue growth:  2244. 20 % 92. 55 % 19. 15 %
revenue/share:  1. 27   13. 27   55. 24  

beta (1yr vs S&P500):  1. 66   1. 24   0. 93  
sharpe (1yr):  -1. 70   0. 29   0. 60  

held % insiders:  2. 11 % 6. 38 % 3. 38 %
held % institutions:  114. 84 % 78. 60 % 68. 65 %

Research more with google or yahoo!
the data below are updated and published after 9pm EDT each trading day

2019-04-19 : ADMS
.        + 0 =             0 :: INITIAL WEIGHT
.   + 36.654 =        36.654 :: spline projection addition
.    x 1.432 =        52.489 :: industry recommendation factor
.    x 1.596 =        83.777 :: symbol recommendation factor
.    x 1.037 =        86.846 :: EV/R factor
.    x 0.997 =         86.55 :: return on assets factor
.    x 0.983 =        85.096 :: return on equity factor
.    x 4.327 =       368.185 :: revenue growth factor
.    x 2.332 =       858.475 :: current ratio factor
.    x 1.061 =       910.881 :: quick ratio factor
.    x 1.066 =       970.871 :: short ratio factor
.    x 2.019 =      1960.352 :: price-to-book factor
.    x 1.352 =      2650.507 :: debt-to-equity factor
.    x 2.155 =      5713.138 :: P/E weight
.    x 2.209 =     12620.088 :: PE/G factor
.    x 1.554 =     19617.057 :: beta factor
.    x 0.347 =      6814.861 :: sharpe factor
.    x 0.955 =      6507.193 :: target low factor
.     x 0.97 =      6311.927 :: target mean factor
.    x 1.068 =      6739.442 :: target high factor
.    x 1.312 =      8839.778 :: industry 2-weeks return factor
.    x 0.951 =      8408.413 :: "drift" penalty 1 days ago
.    x 0.997 =       8381.61 :: "drift" penalty 3 days ago
.    x 0.953 =      7983.516 :: "drift" penalty 4 days ago
.     x 0.97 =      7743.604 :: overall "drift" factor
.    x 0.999 =      7732.964 :: largest single-day jump factor
.    x 0.092 =       709.446 :: low price factor
.      x 1.0 =       709.332 :: factor hist industry gain for week 15
.   cubeRoot =         8.918 :: reduced to standardize
.   - 23.534 =         0.442 :: add/subtract for performance
.                      0.442 :: FINAL WEIGHT for NASDAQ:ADMS


 


News feed RSS items generated from finance.google.com

News feed formatting by feed2js.org